Recordati is a global pharmaceutical company that develops and commercializes medicines to serve people living with common and rare diseases in around 150 countries.

Recordati

Lakto-App

jsDelivr

Cloudflare JS

CDN JS

YouTube

Amazon Route 53

Amazon CloudFront

Amazon S3 CDN

DigiCert SSL

OSS CDN

Smart App Banner

Walter Wenninger

Fritz Squindo

Chief Financial Officer

Alessandro R.

CMC Regulatory Affairs Specialist

Anshul Tandon

HR Director - LATAM, APAC, CIS and Switzerland

Rob Koremans

Chief Executive Officer

Giovanni Minora

Director Corporate Audit & Compliance, Data Protection

Alberto Recordati

Vice Chairman

Greater New York Area Acquired Companies With More Than 10 Employees

Manufacturing Companies With More Than 50 Employees (Top 10K)

Northeastern US Companies With More Than $100M in Revenue

Biotechnology Acquired Companies With More Than $1M in Revenue

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America.  A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories.  Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.  Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.

Funding Round - Recordati

Lebanon

New Jersey

United States

North America

Recordati has bought back its own shares for more than EUR2 million

Recordati acquires rights to Enjaymo

Recordati pushes Mib; oil stocks well

Sanofi sells an anti-anemia treatment to Italy's Recordati

Milan stock exchange starts well in negative week, Recordati soars, oil and Tim do well

Recordati, agreement to acquire global rights to Enjaymo

European indexes close up, Recordati good on Mib.

Piazza Affari in the green; agreement pushes Recordati

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

Recordati Signs $825 Mln Deal With Sanofi To Buy Global Rights To Enjaymo

Microsoft Outlook

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Recordati Industria Chimica e Farmaceutica S.p.A.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 27, 2024 4:19 PM	79db08e8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 4:19 PM	419a2ce2
crunchbase trigger	general	Nov 18, 2024 2:12 PM	d84a968d
crunchbase profile	general	Nov 18, 2024 7:27 PM	c3967c3a
li profile	general
translate crunchbase fundingrounds	general	Nov 18, 2024 7:57 PM	353fdc01
peers	general	Sep 27, 2024 4:19 PM	03f83101
news basic	general	Sep 27, 2024 4:19 PM	abf87c68
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:RECORDATI

Recordati

Last Close

52.10

25/11 09:22

Market Cap

10.31B

Beta: -

Volume Today

29.95K

Avg: -